Actinogen Medical: XanaMIA results due in November

Actinogen's pivotal XanaMIA Alzheimer's trial readout is due in November, backed by A$21.9 million cash and plans for a pharma partnership if positive.

• November readout approaches: Actinogen's pivotal XanaMIA trial completed its last patient visit in September, with 247 patients across two countries and a 36-week treatment period; top-line results due November.
• Cash runway secured: Pro-forma cash position stands at A$21.9 million, bolstered by an earlier capital raise plus roughly A$5 million from unlisted option exercises, giving flexibility heading into the readout.

Themes, sentiment and reasons are AI-written paraphrases, checked so they never quote an episode. They may contain errors. Not investment advice. Episodes remain the property of their creators.